Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
Home
About
Our Commitment
Our Leadership
Our Facilities
Science
Our Discovery
Our Target
Our Publications
Platform
BDDS™ Platform
Core Technologies
Nanomedicine in Action
Pipeline
Our Programs
Our Focus Areas
Investors
News
Careers
KR
EN
KR
Home
»
Press Releases
NEWS
Press Releases
Filter
Press Release
Press Release
BIORCHESTRA Wins Grand Prize in 2023 Merck Advance Biotech Grant Program
July 17, 2023
Recognition of outstanding in-vivo outcomes from a lead RNA program in CNS Underpinned by proprietary…
Press Release
BIORCHESTRA Scientific Founder, Chairman, and Chief Executive Officer Joins the Republic of Korea (ROK) Official State Visit to the United States
April 25, 2023
The Official State visit by the President of the Republic of Korea marks the 70th…
Press Release
BIORCHESTRA Announces Significant Progress in Studies of BMD-001 Drug Program
April 24, 2023
Encouraging non-human primate (NHP) findings support the progression of IV-formulated BMD-001 ahead of formal clinical studies for…
Press Release
BIORCHESTRA Expands Executive Leadership Team with the Appointment of David Oxley as Chief Business Officer
April 5, 2023
CAMBRIDGE, Mass. and DAEJEON, South Korea, April 5, 2023 — BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and…
Press Release
BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for Intravenous Delivery of Nucleic Acid Therapies
March 27, 2023
CAMBRIDGE, Mass. and DAEJEON, South Korea, March 27, 2023 — BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and…
Press Release
BIORCHESTRA Participating in Two Upcoming Therapeutic RNA-Focused Events
March 14, 2023
CAMBRIDGE, Mass. and DAEJEON, South Korea, March 8, 2023 /PRNewswire/ — BIORCHESTRA, a biotherapeutics company focused on the treatment of rare…
Press Release
BIORCHESTRA receives Citation from the Korean Minister of Trade, Industry, and Energy
December 15, 2022
A leader in creating jobs through the advancement of RNA-based therapeutics A contributor to a…
Press Release
BIORCHESTRA Announces that its Proprietary Compound, BMD-001, Reduces Amyloid-β and Tau Inflammatory Symptoms in Primate Models for Alzheimer’s Disease at the RNA Leaders USA Conference
November 8, 2022
Boston, MA, November 8, 2022, BIORCHESTRA Co., Ltd., a leading RNA therapeutics company whose lead programs…
Press Release
BIORCHESTRA appointed Dr. Gabriel Helmlinger (Ph.D., DABT) as Head of Translational and Clinical Pharmacology, Toxicology
August 23, 2022
BIORCHESTRA, headquartered in Daejeon, South Korea, appointed Dr. Gabriel Helmlinger (Ph.D., D.A.B.T.) as Vice-President, Head of Translational &…
Press Release
BIORCHESTRA, presenting lead candidate BMD-001 for Alzheimer’s disease and drug delivery system technology at the 2022 BIO International Convention
June 9, 2022
BIORCHESTRA Co., Ltd (BIORCHESTRA), is scheduled to give a company presentation on June 16, 12:00 at…
Press Release
BIORCHESTRA Participated in Formulation and Delivery
May 12, 2022
BIORCHESTRA is a leading RNA therapeutics company that develops novel RNA-based therapeutics and drug delivery…
Press Release
BIORCHESTRA Announces 45 Million USD Series C Fundraising
February 22, 2022
BIORCHESTRA is a leading RNA therapeutics company whose lead programs focus on neurodegenerative diseases using…
Press Release
BIORCHESTRA, SK Biopharmaceuticals collaborate to develop miRNA-targeted therapeutics
January 5, 2022
BIORCHESTRA and SK Biopharmaceuticals announced today that they have forged a partnership to research and…
Press Release
BIORCHESTRA will present data on the therapeutic efficacy of their proprietary ASO against pathological miRNA, a key modulator of neuroinflammation and neurodegeneration, at the CTAD Meeting in Boston
November 30, 2021
South Korean bio-venture BIORCHESTRA Co. Ltd., is an RNA therapeutics firm focused on neurodegeneration. BIORCHESTRA…
Press Release
BIORCHESTRA appoints pharma veteran and Moderna and Akcea (Ionis) CMO “Dr. Louis St. L. O’Dea” as CMO of BIORCHESTRA
September 23, 2021
BIORCHESTRA is a bio-tech company focused on the identification of novel targets in neurodegenerative diseases…
Press Release
Biorchestra Named Awardee in NYC Innovation QuickFire Challenge on Neuroscience
June 24, 2021
Johnson & Johnson Innovation announced today that Biorchestra has been selected as the awardee in…
Press Release
Biorchestra “Discussing the Material Transfer Agreement (MTA) with Big Pharma for Alzheimer’s treatment”
June 25, 2020
Biorchestra announced on the 25th that it has received a proposal for a material transfer…
Press Release
Chong Kun Dang invests ₩5 billion in Biorchestra
August 21, 2019
Chong Kun Dang Holdings said that would invest 5 billion won ($4.1 million) in Biorchestra…
Close Menu
Home
About
Our Commitment
Our Leadership
Our Facilities
Science
Our Discovery
Our Target
Our Publications
Platform
BDDS™ Platform
Core Technologies
Nanomedicine in Action
Pipeline
Our Programs
Our Focus Areas
Investors
News
Careers
BIORCHESTRA Global
KR
EN
KR
© 2023 BIORCHESTRA Co., Ltd. All Rights Reserved